Mrinal Gounder, MD

Memorial Sloan Kettering Cancer Center
New York, New York, United States

Disclosure information not submitted.

Presentation(s):

• Paper 04 - THE PATIENT-REPORTED OUTCOMES (PROS) IN SARCOMA INITIATIVE: TOWARDS A GLOBAL COLLABORATIVE MEASUREMENT STRATEGY

  Thursday, November 2, 2023
  9:00 AM – 10:00 AM  

• Paper 23 - A PHASE IA/IB, DOSE-ESCALATION/EXPANSION STUDY OF THE MDM2-P53 ANTAGONIST BRIGIMADLIN (BI 907828) IN PATIENTS WITH SOLID TUMORS: SAFETY AND EFFICACY IN PATIENTS WITH LIPOSARCOMA

  Thursday, November 2, 2023
  4:00 PM – 5:30 PM  

• Paper 24 - MILADEMETAN VS. TRABECTEDIN IN PATIENTS WITH DEDIFFERENTIATED LIPOSARCOMA: RESULTS FROM THE PHASE 3 MANTRA STUDY

  Thursday, November 2, 2023
  4:00 PM – 5:30 PM  

• Paper 25 - PRELIMINARY RESULTS FROM A PHASE 1 STUDY OF FHD-609, A BROMODOMAIN-CONTAINING PROTEIN 9 DEGRADER, IN PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR SMARCB1-LOSS TUMORS

  Thursday, November 2, 2023
  4:00 PM – 5:30 PM  

• Paper 41 - PDGFRβ AND C-ABL ACTIVATION ASSOCIATE WITH OUTCOME AND RESPONSE TO SORAFENIB IN DESMOID PATIENTS TREATED ON THE PHASE III ALLIANCE A091105 TRIAL

  Friday, November 3, 2023
  11:30 AM – 12:30 PM